Table 1. Recent and ongoing clinical trials for BRAF mutant CRC.
| Strategy | Therapy | Ongoing vs. completed | Response rate, n [%] | Reference |
|---|---|---|---|---|
| BRAF monotherapy | Vemurafenib | Completed | 1/19 [5] | (18) |
| BRAF + MEK | Dabrafenib + trametnib | Completed | 5/43 [12] | (25) |
| BRAF + EGFR | Vemurafenib + cetuximab | Ongoing | 2/27 [7] | (26) |
| BRAF + EGFR | Vemurafenib + panitumumab | Completed | 2/15 [13] | (27) |
| BRAF + EGFR | Encorafenib (LGX818) + cetuximab | Ongoing | 6/26 [23] | (28) |
| BRAF + EGFR | Dabrafenib + panitumumab | Ongoing | 2/15 [13] | (29) |
| BRAF + EGFR + MEK | Dabrafenib + panitumumab + trametinib | Ongoing | 6/15 [40] | (28) |
| BRAF + EGFR + PI3Kα | Encorafenib + cetuximab + alpelisib (BYL719) | Ongoing | 7/28 [25] | (29) |
| BRAF + EGFR + cytotoxic | Vemurafenib + cetuximab + irinotecan | Ongoing | 4/9 [44] | (30) |
BRAF, V-raf murine sarcoma viral oncogene homolog B; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; MEK, mitogen-activated extracellular signal-related kinase kinase.